Quick Answer
Damora Therapeutics, Inc. reported Stockholders Equity of $240.38 million for fiscal year 2025.
Damora Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $240.38M | +1418.4% |
| 2024 | $15.83M | -51.0% |
| 2023 | $32.33M | -47.6% |
| 2022 | $61.75M | -47.3% |
| 2021 | $117.22M | -29.2% |
| 2020 | $165.49M | +332.6% |
| 2019 | -$71.15M | -110.3% |
| 2018 | -$33.84M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.01M | -61.8% | -26.9% |
| June 30, 2025 | $10.95M | -53.6% | -20.1% |
| March 31, 2025 | $13.71M | -51.3% | -13.4% |
| December 31, 2024 | $15.83M | -51.0% | -24.4% |
| September 30, 2024 | $20.93M | -44.0% | -11.2% |
| June 30, 2024 | $23.59M | -46.0% | -16.2% |
| March 31, 2024 | $28.16M | -44.1% | -12.9% |
| December 31, 2023 | $32.33M | -47.6% | -13.5% |
- Damora Therapeutics, Inc. showed an increase of +1418.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Damora Therapeutics, Inc.’s stockholders equity has grown by 810.4% (from -$33.84 million to $240.38 million).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: